Sakshi Tomar

Employment

• National Institutes of Health Visiting Fellow
  2019 - Present
• Gladstone Institute of Virology and Immunology Postdoctoral scholar
  2016 - 2019

Education

• Purdue University PhD
  2010 - 2016

Projects & Funding

Projects & funding information is unavailable.

Publications (35)

• Data from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
  2023 DOI: 10.1158/1535-7163.c.6543480
  +Save
• Supplementary Table from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
  2023 DOI: 10.1158/1535-7163.22522749.v1
  +Save
• Supplementary Table from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
  2023 DOI: 10.1158/1535-7163.22522752.v1
  +Save
• Supplementary Table from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
  2023 DOI: 10.1158/1535-7163.22522755.v1
  +Save
• Supplementary Table from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
  2023 DOI: 10.1158/1535-7163.22522758.v1
  +Save
• Supplementary Table from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
  2023 DOI: 10.1158/1535-7163.22522761.v1
  +Save
• Supplementary Table from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
  2023 DOI: 10.1158/1535-7163.22522761
  +Save
• Supplementary Table from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
  2023 DOI: 10.1158/1535-7163.22522749
  +Save
• Supplementary Table from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
  2023 DOI: 10.1158/1535-7163.22522752
  +Save
• Supplementary Table from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
  2023 DOI: 10.1158/1535-7163.22522755
  +Save